US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
From Cybin Inc.
Via Business Wire
News headline image
Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
From Cybin Inc.
Via Business Wire
News headline image
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
From Cybin Inc.
Via Business Wire
News headline image
Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021
From Cybin Inc.
Via Business Wire
News headline image
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
From Cybin Inc.
Via Business Wire
News headline image
Cybin to Present at the Jefferies Virtual Healthcare Conference 2021
From Cybin Inc.
Via Business Wire
News headline image
Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions
From Cybin Inc.
Via Business Wire
News headline image
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
From Cybin Inc.
Via Business Wire
News headline image
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Cybin to Present at the Benzinga Global Small Cap Conference
From Cybin Inc.
Via Business Wire
News headline image
Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003
From Cybin Inc.
Via Business Wire
News headline image
Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
From Cybin Inc.
Via Business Wire
News headline image
Cybin to Present at the Bloom Burton & Co. Healthcare Investor Conference
From Cybin Inc.
Via Business Wire
News headline image
Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back
From Cybin Inc.
Via Business Wire
News headline image
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
From Cybin Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >